The US Food and Drug Administration should give sponsors flexibility in setting enrollment goals for clinical trial diversity action plans and further clarify how to balance enrollment between US and foreign sites in multinational studies, industry groups said.
Industry Seeks Flexibility, Clarity On US FDA Clinical Trial Diversity Action Plan Requirements
Draft guidance recommendations on setting enrollment goals lead PhRMA and BIO to seek assurances of FDA flexibility absent reliable disease prevalence data.
